Australia's most trusted
source of pharma news
Tuesday, 23 April 2024
Posted 3 August 2022 PM
Despite a three year stint on CSL's board before taking up the job of CEO at Vifor, it's been revealed that Abbas Hussain will not be welcomed back to the CSL-fold once the acquisition deal goes through.
Hussain, will be out the door after almost exactly one year in the top job, according to details disclosed late yesterday confirming CSL's acquisition of Vifor.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.